This article is a correction to:
Therapeutic potential of topical administration of acriflavine against hypoxia-inducible factors for corneal fibrosis
Shuyan Zhu1Huimin Shan2Jianqiao Li2
Lijie Pan2Shudan Wang3Jing Zhu2Hui Guo2Fenghua Mi2Xinyi Wu2Jia Yin3*
Kunpeng Pang2*- 1Xi’an People’s Hospital (Xi’an Fourth Hospital), Shanxi Eye Hospital, Xi’an, China
- 2Department of Ophthalmology, Qilu Hospital of Shandong University, Jinan, Shandong, China
- 3Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, MA, United States
A Corrigendum on
Therapeutic potential of topical administration of acriflavine against hypoxia-inducible factors for corneal fibrosis
by Zhu S, Shan H, Li J, Pan L, Wang S, Zhu J, Guo H, Mi F, Wu X and Pang K (2022). Front. Pharmacol. 13:996635. doi: 10.3389/fphar.2022.996635
In the published article, there was an error in the Author list, and author “Jia Yin” was erroneously excluded. The corrected Author list appears below.
“Shuyan Zhu1, Huimin Shan2, Jianqiao Li2, Lijie Pan2, Shudan Wang3, Jing Zhu2, Hui Guo2, Fenghua Mi2, Xinyi Wu2, Jia Yin3*, Kunpeng Pang2*.”
In the published article, Jia Yin’s information was not included in the correspondence information. The corrected Correspondence information is “Jia Yin, jia_yin@meei.harvard.edu; Kunpeng Pang, k.pang@sdu.edu.cn.”
In the published article, the Author Contributions statement did not mention Jia Yin’s contributions. The correct statement is “JY and KP contributed to conception and design of the study. KP supervised the study. SZ, HS, SW, and KP conducted experiments and acquired data; HS and KP wrote the manuscript; LP analyzed data; FM assisted in conducting the experiments; JZ and HG assisted in analyzing data; JL and XW provided the reagents; KP designed research studies and revised the manuscript.”
In the published article, the Acknowledgements statement was displayed as “We thank Dr. Jia Yin as an advisor for the hypoxia study.” The correct statement is “None.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: HIF, corneal fibrosis, corneal hypoxia, TGF-β1, extracellular matrix
Citation: Zhu S, Shan H, Li J, Pan L, Wang S, Zhu J, Guo H, Mi F, Wu X, Yin J and Pang K (2023) Corrigendum: Therapeutic potential of topical administration of acriflavine against hypoxia-inducible factors for corneal fibrosis. Front. Pharmacol. 14:1161682. doi: 10.3389/fphar.2023.1161682
Received: 08 February 2023; Accepted: 09 February 2023;
Published: 21 February 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Zhu, Shan, Li, Pan, Wang, Zhu, Guo, Mi, Wu, Yin and Pang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jia Yin, amlhX3lpbkBtZWVpLmhhcnZhcmQuZWR1; Kunpeng Pang, ay5wYW5nQHNkdS5lZHUuY24=